RBC's Brian Abrahams holds a mock adcomm on Biogen's iffy aducanumab data — and most of these experts don't see a path to an approval
As catalysts go, few loom larger than the aducanumab adcomm slated for Nov. 6.
With its big franchise under assault, Biogen is betting the ranch that its mixed late-stage Alzheimer’s data can squeak past the experts and regulators and get onto the market. And the topic — after a decade of Alzheimer’s R&D disasters in what still represents the El Dorado of drug markets — remains in the center ring of discussions around late-stage pipeline prospects.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
